
HCAT Stock Forecast & Price Target
HCAT Analyst Ratings
Bulls say
Health Catalyst is currently facing challenges with stabilizing and growing their go-forward business after the divestiture of Vitalware, which accounted for a larger portion of their recent adj-EBITDA than expected. Further divestitures may be in the works but it is uncertain if they will have a significant impact on the company's financials. Their recent revenue decline can be attributed to the restructuring of lower-margin services, but their technology segment continues to show promise and beat consensus.
Bears say
Health Catalyst is facing a challenging operating environment with a longer sales cycle and increased competition in the healthcare data and analytics market. Their recent guidance revisions and decline in annual revenue for FY27 are mainly driven by the migration of legacy contracts to newer, lower-priced offerings, leading to increased pressure on customer retention and a negative mix shift in their business. Additionally, the overall slowdown in M&A activity and focus on profitability could further impact their growth potential. Overall, the negative outlook on Health Catalyst is driven by these fundamental factors and the potential for continued underperformance in the near term.
This aggregate rating is based on analysts' research of Health Catalyst Inc and is not a guaranteed prediction by Public.com or investment advice.
HCAT Analyst Forecast & Price Prediction
Start investing in HCAT
Order type
Buy in
Order amount
Est. shares
0 shares